Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.

Abstract

INTRODUCTION:

Pralatrexate is a novel antifolate agent that belongs to the class of 10-deazaaminopterins. Its clinical efficacy as a single agent in relapsed or refractory peripheral T-cell lymphoma (PTCL) has been established in randomized trials. Treatment with this agent is generally safe.

AREAS COVERED:

This paper discusses the pharmacokinetics and efficacy of pralatrexate in T-cell lymphoma in clinical trials. In addition, the authors highlight pralatrexate-associated adverse effects and safety concerns.

EXPERT OPINION:

Although established as a second-line therapy, pralatrexate offers a clinical benefit to less than one-third of patients with PTCL. In addition, toxicity of this agent can be significant, especially mucositis, immunosuppression and thrombocytopenia. Currently, the potential synergy between pralatrexate and other agents in T-cell lymphoma is being explored in a number of studies. These results will hopefully prove the validity of this approach, leading to improved quantity of life in these patients, with an acceptable comfort index.

• Authors: Alexei Shimanovsky, Constantin A Dasanu
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 14 Issue 4 Pg. 515-23 (Mar 2013) ISSN: 1744-7666 [Electronic] England
• PMID: 23409799 (Publication Type: Journal Article, Review)

Chemical References

• 10-propargyl-10-deazaaminopterin
• Folic Acid Antagonists
• Aminopterin

Topics

• Aminopterin (administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
• Animals
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Clinical Trials as Topic
• Disease-Free Survival
• Drug Screening Assays, Antitumor
• Folic Acid Antagonists (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Humans
• Lymphoma, T-Cell (drug therapy)